Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
A Randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysed Chronic Renal Failure Patients
Authors
1Nephrology Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, IR Iran
21) Nephrology Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences. 2) Brain and Spinal Injury Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, [email protected], IR Iran
*Corresponding Author: 1) Nephrology Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences. 2) Brain and Spinal Injury Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, [email protected], IR Iran. Tel: 98-9125146752. Fax: +98-2166581560. Email: [email protected]
Published online:May 31, 2012
Article type:Research Article
Received:Oct 23, 2011
Accepted:Mar 28, 2012
How to Cite:Ahmadi F, Ramezani M, Razeghi E, Ranjbarnovin N, Khazaeipour Z. A Randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysed Chronic Renal Failure Patients. Hepat Mon. 2012;12(5):. doi: https://doi.org/10.5812/hepatmon.6438
Abstract
Background: Patients with chronic renal disease should be vaccinated as soon as dialysis is forestalled, and this could improve the seroconversion of hepatitis B vaccination.
Objectives: In this study, we aimed to compare seroconversion and immune response rates using 4 doses of 40 μg and 3 doses of 20 μg Euvax B recombinant Hepatitis B surface Antigen (HBs Ag) vaccine administered to predialysis patients with chronic kidney disease (CKD).
Patients and Methods: In an open, randomized clinical trial, we compared seroconversion rates in 51 predialysis patients with mild and moderate chronic renal failure who received either 4 doses of 40 μg or 3 doses of 20 μg of Euvax B recombinant hepatitis B vaccine administered at 0, 1, 2, 6 and 0, 1, 6 months, respectively.
Results: Differences in seroconversion rates after 4 doses of 40 μg (80.88%) compared to 3 doses of 20 μg (92%) were not significant (P = 0.4124). The mean HBs antibody level after 4 doses of 40 μg at 0, 1, 2, and 6 months (182.2 ± 286.7) was significantly higher than that after 3 doses of 40 μg at 0,1, and 6 months (96.9 ± 192.1) (P = 0.004). Seroconversion after 4 doses of 40 μg (80.8%) was also significantly higher than that after 3 doses of 40 μg (77%) (P = 0.004). Multivariable analysis showed that none of the variables contributed to seroconversion.
Conclusions: We found that 4 doses of 40 μg did not lead to significantly more seroconversion than 3 doses of 20 μg.
Implication for health policy/practice/research/medical education:
This article presents Hepatitis B Vaccination in Patients with chronic renal disease.
Please cite this paper as:
Ahmadi F, Ramezani M, Razeghi E, Ranjbarnovin N, Khazaeipour Z. A randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysed Chronic Renal Failure Patients. Hepat Mon. 2012;12(5): 344-8. DOI: 10.5812/hepatmon.6438
NCT registration identifier:
NCT01468051
Copyright © 2012 Kowsar Corp. All rights reserved.
Copyright
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
31
Oct
2011
Efficacy of HBV Vaccination in Various Stages of Chronic Kidney Disease: Is Earlier Better?
Behnam Hashemi,
Mitra Mahdavi-Mazdeh,
Mohammadreza Abbasi,
Seyed Mohammadmehdi Hosseini-Moghaddam,
Nadia Hatmi Zinat,
Farrokhlagh Ahmadi
Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam S, Hatmi Zinat N, et al. Efficacy of HBV Vaccination in Various Stages of Chronic Kidney Disease: Is Earlier Better?. Hepat Mon. 2011;11(10):. doi: https://doi.org/10.5812/kowsar.1735143X.751
10
Apr
2017
Efficacy and Safety of Reinforced Versus Standard Vaccine Schedule Towards Hepatitis B In Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Fabrizio Fabrizi,
Francesca Maria Donato,
Piergiorgio Messa
Fabrizi F, Maria Donato F, Messa P. Efficacy and Safety of Reinforced Versus Standard Vaccine Schedule Towards Hepatitis B In Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Hepat Mon. 2017;17(7):e44179. doi: https://doi.org/10.5812/hepatmon.44179
14
Nov
2012
Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients
Alicja E. Grzegorzewska
Grzegorzewska AE. Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients. Hepat Mon. 2012;12(11):7359. doi: https://doi.org/10.5812/hepatmon.7359
31
Mar
2007
Source and Response of Antibody to Hepatitis B Vaccine in Hemodialysis Patients
Zohreh Aminzadeh,
Hossein Akhavan,
Latif Gachkar
Aminzadeh Z, Akhavan H, Gachkar L. Source and Response of Antibody to Hepatitis B Vaccine in Hemodialysis Patients. Hepat Mon. 2007;7(1):. doi:
31
Mar
2007
The Effect of Inflammatory Reactions on Antibody Unresponsiveness to Hepatitis B Vaccine in Hemodialysis Patients
Dede Sit,
Ali Kemal Kadiroglu,
Hasan Kayabasi,
Zulfukar yilmaz,
Mehmet Emin Yilmaz
Sit D, Kadiroglu A, Kayabasi H, yilmaz Z, Yilmaz M. The Effect of Inflammatory Reactions on Antibody Unresponsiveness to Hepatitis B Vaccine in Hemodialysis Patients. Hepat Mon. 2007;7(1):. doi:
Cited by
- Scopus by DOI: 20
Last Update: 3 weeks ago
- Scopus by Title: 20
Last Update: 3 weeks ago
- Scopus by Title (Ref): 20
Last Update: 3 weeks ago
- CrossRef: 14
Last Update: 1 day ago
Comments
Number of Comments:0